Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
As any healthcare worker will tell you, it in in stressfukl times
As any healthcare worker will tell you, it is stressful times that early stage dementia symptons are first evident. So, whilst condemning the weasel pulling of the dividend i note that they are reviewing all "discretionary" expenditure.
Well, let me remind them, lavish Directors Remuneration (laughably referred to as 'compensation') is discretionary. If things are so bad can we expect 50% reductions? Or, are they content simply to bash shareholders by using the PRA as cover?
Oh yes! Maybe there is hope - their memory is not so bad as to continuing to access their own share based awards!!
But, Oh dear! They seem to be forgetting that they are allowed to open their wallets and buy shares in the market - an action notable by its absence.
TOTAL DISGRACE - The BOD should be locked away in a secure facility.
No, i do not think that we are too late. There is a lot of news about tests in development but any & every new test has to be clinically validated. So, whilst we may not be in the vanguard here, the timeline given is a "clinically validated" test in 8 weeks, now 7 weeks. That will trump many competitors. And the market? Testing whole populations over multiple geographies. Genedrives time has come.
The key word in today's RNS is Exosomes. I have little doubt that they are exploring, via exosomes, the potential for delivery of intercellular anti-viral payloads. A useful reference is the very recent announcement by Nasdaq listed Orgenisis.
Yes, Pooks. Divi cancelled but seems no salary sacrifice by the BOD. In fact looks like another load of share options has been doshed out. Provident's loan customers mainly operate Friday to Friday or month end to month end. Life is a struggle. Not apparently for the BOD. Call me cynical if you like but there seems to be an almost imperial lofty disdain here & it smells.
So, faced by the challenge of Covid-19 & the collapsing oil price and heavily indebted they pull the divi - that's fine & then reduce their remuneration by 10% - that is truly pathetic. In fact an insult, a slap in the face.
The RNS stated that GDR believes that the current major problem for widespread testing is supply chain logistics. The is borne out in spades by today's news programmes.
Next announcement is lilely to be a partnership. Could be with a major.
M&C is trekking towards all time lows. In addition to the financial misreporting & the ongoing FCA investigation we have the hammer blow of coronavirus trading headwinds [more of a full blown gale than a headwind]. So what a time to have your £36m banking facility up for renogiation on 30th Apri. The market smells blood.
Look at Rock Rose announvement today & their cash balances. I wonder whether a farm out to RR or maybe RR simply deploy some cash to buy them out. Remember their opportunistic bid for Independent O & G which failed. Both i3 & I O&G are next door to RR.
My personal opinion is to keep the faith. The genie is out of the bottle & unlikely to be put back.
Worry not RedB - I saw an analyst comment that sales of dresses etc would fall off a cliff as no woman will buy a new dress if there is nowhere to go. Whoever he [& it must have been a he] was then he doesn't understand women! Of course nobody is buying anything, other than provisions in the "panic" period but once that has passed [is passing?], sitting at home with nothing to do then it will be a different matter. Enormous opportunities for SOS. Nonethleless would have been nice to see the BOD cutting their remuneration & dipping their hands into their pockets to pick up some cheaop shares.
I am no scientist but as for the maths: 10000 tests per hour = 240,000 potential per 24 hours. The big problem for those who call for widespread NHS testing for front line staff is that any one of us is only as safe as the last person that they had contact with. So whereas the antibody test is excellent for onetime testing to prove any previous infection the GDR test provides the facility for repeat testing, ie those NHS staff to be tested weekly, thus giving reassurance to staff and patients alike.
The proposed fundraise was underwritten so clearly a rights issue. But the underwriting was only on a "stand by" basis which, it seems to me doesn't really mean anything. It is saying " we agree to underwrite but on terms to be decided only when we know the price". I do not think that COST have any responsibility to them or to their advisers who basically said "let's fly a kite" only to see it promptly shot out of the skies. Frankly the advisers should be ditched for such a cavalier approach in a febrile market. And, as for the putative stand-by underwiters I suggest that they employ some social distancing. This company is far from being a dead duck but for rehabilitation to take pace a long period of good stewardship & recognition of their shareholder base is necessary.
The point about GDR is that , despite its modest size, it has credibility. The pathogen deat with the US defence is proof enough of that. And the HCV field test, although not yet achieving sales traction, has undoubted utility. The Antibiotic Induced Hearing Loss test, currently in NHS evaluation could become the defacto test in developed health service settings globally. After all, if a baby suffers hearing loss because of an inappropriate antibiotic when there is a readily available loss, then the costs of compensation for a lifetime disability is enormous. Now we have the Covid-19 test assay & this will be taken seriously because GDR is a serious and respected company. None of this will be lost on the American majors, Abbott Labs - Baxters - Becton Dickinson. And the market cap is derisory for such potential - the current news being merely the trigger for a re- evaluation. So, expect a partnership or even an opportunistic takeover approach which, I feel, would have to be north of £50m.
So, current MC is £11m. Bearing in mind a credible company with a credible, high throughout test for Covid-19 just weeks away the potential is obvious. If Covid-19 represents potential Armaggedon then the GDR test is ammunition to take into the battle. I think that a perfectly realistic market cap as of now would be £25-£30m.
Accurate & high throughput test. This is gold-dust. With a current cap of little over £5m GDR is heading for the moon.
Whatever is wrong with lse. Share deals only uo to 11am - same on Friday. Woeful.
A Budget plus for AFC was the removal of the red diesel subsidy for all commercial users other than agriculture from 2022. AFC's plans for generators now become even more attractive for industry in gneral & civil engineering firms in particular [who, of course, work on very slim margins].
This company has now lost all credibility. What a totally incompetent way to go about a fundraise, especially as it does not appear to be wholly necessary. To think that advisers are being paid loadsamoney for lousy advice.
Liquidity constraints should not be a surprise, the question is how & whether they can navigate the. The relatively good news is that there is not, so far, a share suspension. With this stock now you "pay your money & take your chance". At worst a wipeout & at best, over time, a return of multiples of the current price.